H. pylori gastritis should be considered as an infectious disease, even as an infectious disease, regardless of the presence or absence of symptoms or complications (e.g. ulcers or gastric cancer). The most common cause of chronic gastritis worldwide is H. pylori infection, which causes progressive damage to the gastric mucosa and has now been found to be associated with other diseases such as duodenal ulcer, gastric ulcer, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. Among them, H. pylori-induced gastritis is considered to be the most important risk factor for peptic ulcer as well as gastric cancer. H. pylori infection can lead to serious complications and is infectious for life, therefore eradication therapy is recommended for all H. pylori-infected patients (unless limited by other factors). The pathological development of gastric cancer can be summarized as follows: normal gastric mucosa → chronic superficial gastritis → chronic atrophic gastritis → intestinal metaplasia → heterogeneous hyperplasia → gastric cancer. For asymptomatic H.pylori-infected patients, the best time for eradication therapy is before gastric mucosal atrophy occurs; H.pylori eradication can prevent gastric carcinogenesis, and the degree of risk reduction depends on the severity and extent of gastric mucosal atrophy at the time of eradication. The preferred non-invasive method for detecting hp infection: the 13C or 14C-urea breath test, and the blood hp antibody test carried out in many medical screening centers is not accurate. The bismuth quadruple regimen is the eradication regimen currently recommended by our guidelines. The eradication rate in the European multicenter large sample study was 93% by protocol (PP) analysis and 80% by intention-to-treat (ITT) analysis, while the 7-d eradication rate of the standard triplet regimen as a control was only 70% and 55%. Domestic studies also showed that the classical quadruple regimen had 10-d eradication rates of 89.4% (ITT) and 91.6% (PP), while the standard triple regimen as a control had 7-d eradication rates of 63.5% and 65.1% (PP). Our multicenter, large-sample study showed an eradication rate of 75.2% for the classical sequential therapy PP analysis.